Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 121,777,889 | 113,630,164 | 108,300,329 | 100,963,692 | 111,444,313 | 556,116,387 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 121,777,889 | 113,630,164 | 108,300,329 | 100,963,692 | 111,444,313 | 556,116,387 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 3,345,342 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 552,771,045 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 121,777,889 | 113,630,164 | 108,300,329 | 100,963,692 | 111,444,313 | 556,116,387 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 6,303,751 | 5,346,565 | 5,942,288 | 3,455,907 | 5,237,546 | 26,286,057 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | |||||
| 11 | Total support. Add lines 7 through 10 | 582,732,878 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2020 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2020 |
(iii) Distributable Amount for 2020 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2020 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2020: | ||||
| a From 2015....... | ||||
| b From 2016....... | ||||
| c From 2017....... | ||||
| d From 2018....... | ||||
| e From 2019....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2020 distributable amount | ||||
|
i
Carryover from 2015 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2020 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2020 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2020, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2020. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2021. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2016..... | ||||
| b Excess from 2017..... | ||||
| c Excess from 2018..... | ||||
| d Excess from 2019..... | ||||
| e Excess from 2020..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990 , PART I, LINE 1 & PART III, LINE 1 | ORGANIZATIONS MISSION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. |
| FORM 990, PART III, LINE 4 | Sanford Burnham Prebys is an independent nonprofit medical research organization dedicated to uncovering the origins of disease and launching bold new strategies that lay the foundation for cures. Our Institute has deep expertise in fundamental biology and is one of the most comprehensive drug discovery centers in the nonprofit world. Cancer Researchers reveal the internal signals that cells use to maintain energy: Scientists at Sanford Burnham Prebys took a deep dive into a previously overlooked family of proteins and discovered that they are essential to maintaining the energy that cells need to grow and survive. The proteins, known as lipid kinases, produce messengers that help balance cellular metabolism and promote overall health. The findings, published in Developmental Cell, support the pursuit of lipid kinases as promising therapeutic targets for diseases that demand excess energy, such as cancer. Tumor marker may help overcome endocrine treatment-resistant breast cancer: A study led by Svasti Haricharan, Ph.D., identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research, published in Nature Communications, offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes the growth of cancer cells, to avoid disease relapse. Atomic-level insights gained for a key lipid-binding protein implicated in cancer: Francesca Marassi, Ph.D., led research published in Structure that identifies hotspots within a protein called PLEKHA7 as targets for drugs. The drug interacts with a cell's membrane to regulate important intercellular communications and may be key to designing treatments for advanced colon, breast and ovarian cancers. Scientists identify potential drug candidates for deadly pediatric leukemia: Ani Deshpande, Ph.D., led a study published in Blood that found two existing drug candidates-JAK inhibitors and Mepron-that hold potential as treatments for a deadly acute myeloid leukemia subtype that is more common in children. The foundational study is a first step toward finding effective treatments for the hard-to-treat blood cancer. Starving tumors by blocking glutamine uptake: Scientists at Sanford Burnham Prebys identified a drug candidate that blocks the uptake of glutamine, a key food source for many tumors, and slows the growth of melanoma. The drug, SLC1A5, is a small molecule that offers a promising new approach for treating melanoma and other cancers. The research was published in Molecular Cancer Therapeutics. Scientists shrink pancreatic tumors by starving their cellular "neighbors": Cosimo Commisso, Ph.D., led a Cancer Discovery study that demonstrated for the first time that blocking "cell drinking,micropinocytosis, in the thick tissue surrounding a pancreatic tumor slowed tumor growth-providing more evidence that micropinocytosis is a driver of pancreatic cancer growth and an important therapeutic target. New drug combination shows promise as powerful treatment for AML: Peter Adams, Ph.D., led a study published in Nature that identified two drugs that are potent against acute myeloid leukemia when combined, but only weakly effective when used alone. The researchers were able to significantly enhance cancer cell death by jointly administering the drugs that are only partially effective when used as single-agent therapies. Personalized drug screens could guide treatment for children with brain cancer: A collaborative study led by Sanford Burnham Prebys demonstrated that personalized drug screens can be used to identify new therapeutic candidates for medulloblastoma, the most common malignant brain cancer in children. The proof-of-concept study was published in Cancer Research and is the basis for future clinical trials. Scientists kill cancer cells by "shutting the door" to the nucleus: A proof-of-concept study by scientists at Sanford Burnham Prebys found that blocking the construction of nuclear pore complexes shrank aggressive tumors in mice while leaving healthy cells unharmed. The research, published in Cancer Discovery, revealed a new Achilles heel for cancer that may lead to better treatments for deadly tumors such as melanoma, leukemia and colorectal cancer. Scientists discover novel target for pancreatic cancer: Scientists at Sanford Burnham Prebys uncovered a novel drug target, a protein called PPP1R1B, that stops the deadly spread of pancreatic cancer in mice. Published in Gastroenterology, the findings are a first step toward a potential treatment for one of the deadliest cancers known today. A helping hand for cancer immunotherapy: Scientists at Sanford Burnham Prebys demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 inhibitors are currently in clinical trials for cancer, and this research provides a strong rationale for testing the drugs in tumors that are not responsive to checkpoint inhibitors. The research was published in Science Translational Medicine. Degenerative Diseases Researchers dig deeper into how cells transport their waste for energy: Scientists at Sanford Burnham Prebys gained a deeper insight into the intricacies of autophagy, the process in which cells degrade and recycle cellular components. The findings, published in Current Biology, described how the "trash bags" in a cell-called autophagosomes-are tagged to direct their movement to the cellular "recycling plants" where waste is processed. The research opens new paths to understanding the relationship between autophagy and age-related diseases such as cancer and neurological disorders. Fruit flies reveal new insights into space travel's effect on the heart: Karen Ocorr, Ph.D., led a study that demonstrated how fruit flies that spend several weeks on the International Space Station experience profound structural and biochemical changes to their hearts. The research, published in Cell Reports, suggests that astronauts who spend a lengthy amount of time in space could suffer similar effects and may benefit from protective measures to keep their hearts healthy. Drug guides stem cells to desired location, improving their ability to heal: Scientists at Sanford Burnham Prebys created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and a major advance in the field of regenerative medicine. The discovery, published in Proceedings of the National Academy of Sciences (PNAS), could improve current stem cell therapies for degenerative diseases. Scientists uncover a novel approach to treating Duchenne muscular dystrophy: A collaborative study with scientists in Italy found that drugs that target extracellular vesicles within dystrophic muscles can restore their ability to regenerate muscle. The research, published in EMBO Reports, is a promising new approach to treat this incurable muscle-wasting disease. Scientists identify a new drug target for dry age-related macular degeneration: Researchers revealed that a blood protein called vitronectin is a promising drug target for age-related macular degeneration, a leading cause of vision loss in Americans 60 years of age and older. The study, published in Proceedings of the National Academy of Sciences (PNAS), also holds promise for Alzheimer's and heart disease, which are linked to vitronectin. Human Genetics Study supports gene therapy as a promising treatment for soft bone disease: A preclinical study led by scientists at Sanford Burnham Prebys has established that AAV8-TNAP-D10-a gene therapy that replaces a key enzyme found in bone-may be a safe and effective single-dose treatment for hypophosphatasia (HPP). The study, published in the Journal of Bone and Mineral Research and performed in a murine model of the disease, further supports advancing the therapy toward human clinical trials. Immunity and Pathogenesis Leprosy drug holds promise as at-home treatment for COVID-19: A Nature study authored by scientists at Sanford Burnham Prebys found that the leprosy drug clofazimine, which is FDA approved and on the World Health Organization's List of Essential Medicines, exhibits potent antiviral activities against SARS-CoV-2 and prevents the exaggerated inflammatory response associated with severe COVID-19. Scientists identify "immune cop" that detects SARS-CoV-2: Scientists at Sanford Burnham Prebys identified the sensor in human lungs that detects SARS-CoV-2 and signals that it's time to mount an antiviral response. The research, published in Cell Reports, provides insights into the molecular basis of severe disease and may enable new strategies for the treatment and prevention of COVID-19. Nature study identifies 21 existing drugs that could treat COVID-19: A Nature study authored by a global team of scientists and led by Sumit Chanda, Ph.D., a professor at Sanford Burnham Prebys, identified 21 existing drugs that stop the replication of SARS-C |
| FORM 990, PART VI, LINE 11B | PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE, AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. |
| FORM 990, PART VI, LINE 12C | DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE HAS A CONFLICT OF INTEREST POLICY THAT REQUIRES ALL TRUSTEES, PRINCIPAL OFFICERS OR MEMBERS OF A COMMITTEE WITH BOARD DELEGATED POWERS TO ANNUALLY CONFIRM THEIR RECEIPT OF THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY NEW ASSOCIATIONS OR INTERESTS THAT MIGHT POTENTIALLY POSE A CONFLICT. THIS IS A WRITTEN CONFIRMATION THAT SHE OR HE READ AND UNDERSTANDS THE CONFLICT OF INTEREST POLICY, WILL ABIDE BY THE CONFLICT OF INTEREST POLICY AND CERTIFIES DISCLOSURE OF ALL INTERESTS OR RELATIONSHIPS THAT MAY POSE CONFLICTS. IN ADDITION, EACH YEAR NEW TRUSTEES RECEIVE TRAINING REGARDING THE INSTITUTE'S CONFLICT OF INTEREST POLICY, WHICH INCLUDES HOW TO IDENTIFY A CONFLICT OF INTEREST AND HOW TO HANDLE POSSIBLE CONFLICTS OF INTEREST WHEN THEY ARISE. THE COMPLIANCE DEPARTMENT REVIEWS EACH OF THE STATEMENTS AND ASSESSES WHETHER AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST EXISTS/MAY EXIST AND WHETHER THE INDIVIDUAL SHOULD BE PROHIBITED FROM CONSIDERATION OF RELATED ITEMS. ANY TRUSTEE, PRINCIPAL OFFICER OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WITH A CONFLICT IN A MATTER REQUIRING ACTION BY THE BOARD ARE PROHIBITED FROM PARTICIPATING IN THE BOARD'S DELIBERATIONS AND/OR VOTING ON THE PARTICULAR TRANSACTION OR MATTER IN WHICH HE OR SHE HAS AN INTEREST; AND OTHERWISE REFRAIN FROM EXERTING ANY INFLUENCE TO AFFECT A DECISION. HOWEVER, OTHER MEASURES MAY BE REQUIRED, DEPENDING ON THE NATURE OF AND THE ABILITY TO REASONABLY MANAGE A CONFLICT. |
| FORM 990, PART VI, LINES 15A & 15B | PROCESS FOR DETERMINING COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF THREE INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEO'S COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 10, 2021 FOR THE FOLLOWING POSITIONS: 1) PRESIDENT 2) CAO/CFO 3) VP BUSINESS DEVELOPMENT 4) VP PHILANTHROPY 5) SVP DRUG DISCOVERY & DEVELOPMENT 6) PROGRAM DIRECTOR/PROFESSOR 7) CANCER CENTER DIRECTOR/PROFESSOR 8) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR |
| FORM 990, PART VI, LINE 19 | PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST. |
| Software ID: | |
| Software Version: |